Gastric cancer during pregnancy: a report on 13 cases and review of the literature with focus on chemotherapy during pregnancy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F19%3AN0000157" target="_blank" >RIV/00064173:_____/19:N0000157 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/20:43918759

Výsledek na webu

<a href="https://doi.org/10.1111/aogs.13731" target="_blank" >https://doi.org/10.1111/aogs.13731</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/aogs.13731" target="_blank" >10.1111/aogs.13731</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Gastric cancer during pregnancy: a report on 13 cases and review of the literature with focus on chemotherapy during pregnancy

Popis výsledku v původním jazyce

INTRODUCTION: Gastric cancer during pregnancy is extremely rare and data on optimal treatment and possible chemotherapeutic regimens are scarce. The aim of this study is to describe the obstetric and maternal outcome of patients suffering from gastric cancer during pregnancy and review the literature on antenatal chemotherapy for gastric cancer. MATERIAL AND METHODS: Treatment and outcome of patients registered in the International Network on Cancer, Infertility and Pregnancy (INCIP) database with gastric cancer diagnosed during pregnancy were analyzed. RESULTS: In total, 13 patients with gastric cancer during pregnancy were registered between 2002 and 2018. Median gestational age at diagnosis was 22 weeks (range 6 - 30 weeks). Twelve patients were diagnosed with advanced disease and deceased within 2 years after pregnancy, the majority even within 6 months. In total, 8 out of 10 live births ended in a preterm delivery because of pre-eclampsia, maternal deterioration or therapy planning. Two out of six patients that initiated chemotherapy during pregnancy delivered at term. Two neonates prenatally exposed to chemotherapy were growth restricted and one of them developed a systemic infection with brain abscess after preterm delivery for pre-eclampsia two weeks after chemotherapy. No malformations were reported. CONCLUSIONS: The prognosis of gastric cancer during pregnancy is poor, mainly due to advanced disease at diagnosis, emphasizing the need for early diagnosis. Antenatal chemotherapy can be considered in order to reach fetal maturity, taking possible complications as growth restriction, preterm delivery and hematopoietic suppression at birth into account.

Název v anglickém jazyce

Gastric cancer during pregnancy: a report on 13 cases and review of the literature with focus on chemotherapy during pregnancy

Popis výsledku anglicky

INTRODUCTION: Gastric cancer during pregnancy is extremely rare and data on optimal treatment and possible chemotherapeutic regimens are scarce. The aim of this study is to describe the obstetric and maternal outcome of patients suffering from gastric cancer during pregnancy and review the literature on antenatal chemotherapy for gastric cancer. MATERIAL AND METHODS: Treatment and outcome of patients registered in the International Network on Cancer, Infertility and Pregnancy (INCIP) database with gastric cancer diagnosed during pregnancy were analyzed. RESULTS: In total, 13 patients with gastric cancer during pregnancy were registered between 2002 and 2018. Median gestational age at diagnosis was 22 weeks (range 6 - 30 weeks). Twelve patients were diagnosed with advanced disease and deceased within 2 years after pregnancy, the majority even within 6 months. In total, 8 out of 10 live births ended in a preterm delivery because of pre-eclampsia, maternal deterioration or therapy planning. Two out of six patients that initiated chemotherapy during pregnancy delivered at term. Two neonates prenatally exposed to chemotherapy were growth restricted and one of them developed a systemic infection with brain abscess after preterm delivery for pre-eclampsia two weeks after chemotherapy. No malformations were reported. CONCLUSIONS: The prognosis of gastric cancer during pregnancy is poor, mainly due to advanced disease at diagnosis, emphasizing the need for early diagnosis. Antenatal chemotherapy can be considered in order to reach fetal maturity, taking possible complications as growth restriction, preterm delivery and hematopoietic suppression at birth into account.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30214 - Obstetrics and gynaecology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Acta Obstetricia et Gynecologica Scandinavica

ISSN

0001-6349

e-ISSN

1600-0412

Svazek periodika

99

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

DK - Dánské království

Počet stran výsledku

10

Strana od-do

79-88

Kód UT WoS článku

000491186800001

EID výsledku v databázi Scopus

2-s2.0-85074288798